The Blue Impact Fund aims to raise up to £75 million to catalyse the growth of truly sustainable aquaculture in the UK – with a focus on projects including the production of seaweed, bivalves and land-based shrimp.
Investors looking to support sustainable marine aquaculture and the blue economy need accurate ocean data to make evidence-based decisions and de-risk their financial offerings – but a lack of reliable data might be curtailing their efforts.
Emerging research has shown that nutraceuticals in aquafeed can delay the onset and progress of clinical signs of amoebic gill disease (AGD) in farmed Atlantic salmon.
A side-by-side comparison of conventional and insect-based aquafeed ingredients has found that insect meals and oils come with a larger carbon footprint and require more energy to produce than marine ingredients – but this discrepancy might be short-lived.
Though seaweed operations are diverse – specialising in various species and operating in different economic circumstances – today’s macroalgae practitioners need to stay grounded in science as they work towards their scale and sustainability goals for 2030.
